Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2024-06-20 Annual Report
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
ORAMED PHARMACEUTICALS INC. 2023 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is explicitly titled 'ORAMED PHARMACEUTICALS INC. 2023 ANNUAL REPORT' and contains the standard header for a 'FORM 10-K' filed with the U.S. Securities and Exchange Commission. It includes the required sections for a 10-K, such as 'Item 1. Business', 'Item 7. Management's Discussion and Analysis', and 'Item 8. Financial Statements and Supplementary Data'. It is clearly the official annual report filing. FY 2023
2024-06-20 English
ORAMED PHARMACEUTICALS INC. 2023 ANNUAL REPORT
Audit Report / Information Classification · 95% confidence The document is a filing submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, "Attached hereto is a report on *ARS*" followed by a filename (*ARS_20240620_isa.pdf*). The document itself is very short (1822 characters) and serves primarily to announce the availability of an attached report, rather than being the comprehensive report itself. The term 'ARS' likely stands for Audit Report/Results or a similar regulatory submission. Given the short length and the announcement nature ('Attached hereto is a report on'), this fits the criteria for a Report Publication Announcement (RPA) or potentially a Regulatory Filing (RNS). Since 'AR' (Audit Report / Information) is a specific category, and this document is announcing the publication of an 'ARS' document, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule, as it is announcing the meal rather than being the meal itself. If 'ARS' is interpreted as a specific type of Audit Report, AR could be considered, but the structure strongly suggests an announcement. FY 2024
2024-06-20 English
PROXY STATEMENT OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 1, 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document explicitly states it is a "SCHEDULE 14A" and a "Definitive Proxy Statement" filed by ORAMED PHARMACEUTICALS INC. It contains a "NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 1, 2024" and details the proposals to be voted on, such as the re-election of directors and advisory approval of executive compensation. This content perfectly matches the definition of a Proxy Statement/Information Statement, which corresponds to the filing code DEF 14A (Remuneration Information, which often accompanies proxy statements, but the primary document type here is the proxy statement itself) or PSI (Proxy Solicitation & Information Statement). Given the explicit mention of 'SCHEDULE 14A' and the focus on soliciting proxies for the Annual Meeting, PSI is the most accurate fit for the solicitation material, although DEF 14A covers remuneration which is a key part of the vote. Since PSI covers the solicitation and information statement for the meeting, it is the best primary classification. However, the schema also includes DEF 14A for Remuneration Information, and Schedule 14A filings are often categorized under PSI or DEF 14A depending on the focus. Since the document is a full proxy statement soliciting votes on multiple items including director elections and compensation, PSI (Proxy Solicitation & Information Statement) is the most comprehensive fit for the overall document type, although DEF 14A is also highly relevant due to Proposal 2. I will select PSI as it covers the entire solicitation package.
2024-06-20 English
PROXY STATEMENT OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 1, 2024
Proxy Solicitation & Information Statement Classification · 95% confidence The document explicitly states, 'Attached hereto is a report on *Proxy Statement* *DEF14_20240620_isa.pdf*'. A Proxy Statement, which solicits shareholder votes for a meeting, corresponds to the definition of Proxy Solicitation & Information Statement (PSI). However, the document itself is a very short announcement (1836 characters) stating that the Proxy Statement is attached, which strongly suggests it is a Report Publication Announcement (RPA) according to Rule 2. Furthermore, the document references a 'Proxy Statement' which is often filed on SEC Form DEF 14A. Since the definition for DEF 14A is 'Remuneration Information' and the definition for PSI is 'Proxy Solicitation & Information Statement', PSI is the more accurate classification for the content type (Proxy Statement). Given the short length and the nature of announcing an attached report, RPA is a strong candidate, but since the attached document type (Proxy Statement) has a specific classification (PSI), and the announcement is clearly about that specific document, I must choose between RPA and PSI. The presence of 'Proxy Statement' points directly to PSI. If the document were longer and contained the actual content of the proxy statement, PSI would be certain. Since it is an announcement of the proxy statement, RPA is technically correct based on Rule 2. However, looking at the provided definitions, DEF 14A is specifically for Remuneration, while PSI covers the broader Proxy Solicitation. Given the explicit mention of 'Proxy Statement', PSI is the most semantically accurate classification for the *subject* of the filing, even if the filing *format* is an RPA. I will prioritize the subject matter (Proxy Statement -> PSI) over the announcement format (RPA), as PSI is a defined category for this specific document type, unlike RNS which is a general fallback. The presence of 'DEF14' in the filename also strongly links it to proxy/solicitation materials.
2024-06-20 English
FORM ARS
Annual Report
2024-06-20 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2024-06-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.